(Q44551412)

4 December 2017

title

Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial (English)

1 reference

4 December 2017

1 reference

Andrew J Dowson

1

1 reference

4 December 2017

Bruce R Charlesworth

2

1 reference

4 December 2017

Allan Purdy

3

1 reference

4 December 2017

Werner J Becker

4

1 reference

4 December 2017

Steen Boes-Hansen

5

1 reference

4 December 2017

Markus Färkkilä

6

1 reference

4 December 2017

language of work or name

1 reference

1 January 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

17

1 reference

4 December 2017

issue

11

1 reference

4 December 2017

page(s)

839-851

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200317110-00005

4 December 2017

exact match

0 references

cites work

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

1 reference

12 December 2020

The impact of migraine: Epidemiology, risk factors, and co-morbidities

1 reference

12 December 2020

Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers

1 reference

12 December 2020

Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers

1 reference

12 December 2020

Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet

1 reference

12 December 2020

The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group

1 reference

12 December 2020

Zolmitriptan: a review of its use in migraine

1 reference

12 December 2020

Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90.

1 reference

12 December 2020

Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).

1 reference

12 December 2020

Impact of migraine and migraine therapy on productivity and quality of life

1 reference

12 December 2020

Migraine and reduced work performance: a population-based diary study

1 reference

12 December 2020

Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?

1 reference

12 December 2020

Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine

1 reference

12 December 2020

The impact of migraine on quality of life in the general population: the GEM study.

1 reference

12 December 2020

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

1 reference

12 December 2020

Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey

1 reference

12 December 2020

Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society

1 reference

12 December 2020

Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies

1 reference

12 December 2020

10.2165/00023210-200317110-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

4 December 2017

1004841813

0 references

1 reference